Tuesday, June 07, 2011
Note: clicking on the link below brings up a pdf file
Clinical Trials DayClinical Trials Day • Monday, June 6 is Clinical Trials Day at the Annual Meeting and will feature sessions that focus on a variety of themes relevant to the progress of clinical trials. The series of events will begin on Sunday night with the session “Early-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific?” Sessions taking place on Monday are listed below. For additional session information, see the Clinical Trials track listing.
Monday, June 06, 2011
Welcome to the 2011 Consumers Reforming Health Conference, the inaugural international conference for community engagement in health care. The conference will run from 18th - 20th July 2011 with a public lecture on Sunday 17th of July 2011 at the Melbourne Convention and Exhibition Centre.
The Consumers Reforming Health conference is a conference developed specifically for those with interest in involving consumers in health care, policy and governance. The conference upholds the essential principle that consumer participation is fundamental for health development, clinical governance, community capacity building and health outcomes.
The program aims to demonstrate and enhance this proposition by exploring the experiences, frameworks and practical strategies of participation in a number of health sectors among a diverse range of relevant stakeholders. It intends to broker some new learnings on core principles for future change.
Join other like minded professionals and consumers for the first Consumers Reforming Health conference, Melbourne, 18-20th July 2011.
press release: NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®... -- CHICAGO, June 5, 2011 /PRNewswire/ --
Note: phase 2, single agent study, see tables 1-3 for additional information
Informa Healthcare: Can morphine still be considered to be the standard for treating chronic pain? A systematic review
Sunday, June 05, 2011
Primary Care Doctors and Medical Oncologists Have Different Concerns About Providing Survivorship Care | Cancer.Net ASCO/Patient Pages
"It’s important for patients to talk with both their oncologist and primary care doctor and make sure that information about their treatment and follow-up care recommendations is being shared."
NOCC survivors did a fantastic job on The Dr. Oz Show last week! Our sincere thanks to Dr. Oz, who is an advocate of ovarian cancer awareness, and to those survivors who participated in the show. Together, we are making a difference. Together, we are breaking the silence!
If you missed the show, you can watch it by clicking on the links below.
For Part 1 of The Dr. Oz Show, please click HERE.
For Part 2 of The Dr. Oz Show, please click HERE.
For Part 3 of The Dr. Oz Show, please click HERE.
For Part 4 of The Dr. Oz Show, please click HERE
Medscape article online 7:13pm: (Avastin) Bevacizumab Benefits Patients With Recurrent Ovarian Cancer
Important Note: read the whole article for context of message
extract: Balancing Access and Evaluation in the Approval of New Cancer Drugs, June 8, 2011 — JAMA (patient safety etc)
".....Patients with cancer who lack effective treatment desperately seek novel interventions that might extend their lives. They do not have time to wait for the US Food (blogger's note - or any other nation) and Drug Administration's (FDA’s) regular approval process, which requires that sponsors demonstrate “substantial evidence of clinical benefit (or efficacy) from adequate and well-controlled investigations.”........
Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer, June 8, 2011 JAMA
Objectives To define characteristics of orphan cancer drugs and their pivotal clinical trials and to compare these with nonorphan drugs.
.......More treated patients had serious adverse events in trials of orphan drugs vs trials of nonorphan drugs (48% vs 36%; odds ratio, 1.72; 95% confidence interval, 1.02-2.92; P = .04).
(discussion on stats) extract/s: (Avastin) Bevacizumab and Cancer Treatment-Related Mortality, June 8, 2011 — JAMA
plus Related letters Bevacizumab and Cancer Treatment-Related Mortality Cornelis J. A. Punt, Linda Mol, Miriam Koopman JAMA. 2011;305(22):2292.doi:10.1001/jama.2011.758 Extract Full Text Full Text (PDF) Bevacizumab and Cancer Treatment-Related Mortality Patricia B. Cerrito JAMA. 2011;305(22):2292.doi:10.1001/jama.2011.759 Extract Full Text Full Text (PDF) Bevacizumab and Cancer Treatment-Related Mortality—Reply Shenhong Wu, Vishal Ranpura, Sanjay Hapani JAMA. 2011;305(22):2292-2293.doi:10.1001/jama.2011.760 Extract Full Text Full Text (PDF)
free full access paper + video: Effect of Screening on Ovarian Cancer Mortality, June 8, 2011 JAMA The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
JAMA Report Video This JAMA Report summarizes key findings from the article in video format and includes an interview with one of the authors.
The video script and links to the video are available at http://pubs.ama-assn.org/media/2011jer/0604.dtl#vnrscript
YEARLY OVARIAN CANCER SCREENING ASSOCIATED WITH NO REDUCTION IN DEATH AND INCREASED FALSE POSITIVE TESTS
MLH1/MSH2/MSH6 (Lynch Syndrome) Study Identifies Genetic Mutations Associated With Cancer Risk For Hereditary Cancer Syndrome - media
"The researchers found significant differences in estimated cumulative cancer risk between the 3 mutated genes......"
"This analysis of a nationwide series of 537 families with Lynch syndrome provides age- and gene-specific risk estimates for each tumor of the spectrum. The results should help clarify the phenotypic differences between MSH6, MLH1, or MSH2 mutation carriers and highlight the clinical significance of the risk of gynecological (and especially ovarian) cancers," the researchers conclude."
WHAT IS THE MIMOSA TRIAL?
MIMOSA is a demanding multinational trial started in December 2006 with a 9 years of duration. About 900 patients with advanced ovarian cancer who have had an optimal response to the initial treatment (surgery + chemotherapy) have been included in the study with the aim to test the efficacy and safety of the vaccination with Abagovomab for the prevention or the delay of disease’s recurrences. The first results will be available at the end of 2010.
Saturday, June 04, 2011
Alerts and Notices (Medical Devices) > FDA Safety Communication: Breast Cancer Screening - Thermography is Not an Alternative to Mammography
Purpose:The FDA is issuing this communication to alert the public, including women and health care providers, that thermography is not a replacement for screening mammography and should not be used by itself to diagnose breast cancer. The FDA is not aware of any valid scientific data to show that thermographic devices, when used on their own, are an effective screening tool for any medical condition including the early detection of breast cancer or other breast disease......
Friday, June 03, 2011
2011 ASCO - Patient Pages Doctor-approved cancer information from ASCO | Cancer.Net (annual meeting reports/podcasts, research....)
2011 ASCO Annual Meeting, June 3-7, 2011Watch Cancer.Net for written summaries, podcasts, and videos on breaking cancer research news for patients, families, caregivers, and survivors
Summary measures of quality of care and States' performances relative to all States and the region by:
Overall health care quality
Types of care (preventive, acute, and chronic)
Settings of care (hospitals, ambulatory care, nursing home, and home health)
Five clinical conditions (cancer, diabetes, heart disease, maternal and child health, and respiratory diseases)
Special focus areas on diabetes, asthma, Healthy People 2010, clinical preventive services, disparities, payer, and variation over time
Cancer's Last Stand? The Genome Solution - Wielding Genomes in the Fight Against Cancer - NYTimes.com
"The researchers agreed that there should be global clinical trials of new cancer drugs, and that all patients should have genetic information about their tumors entered into databases that researchers everywhere could study. Dr. Lander said that concerns about genetic privacy had been “fetishized,” and that the potential harm to patients from releasing their genetic information paled next to the harm threatened by their disease."
FYI - (wiki) Terry Fox legacy - Marathon of Hope
press release: EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients Phase 2 Data Presented in ASCO Poster Discussion Session
phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients
Does it run in the family? Toolkit will soon be available at federal health centers nationwide, Genetic Alliance, June 2
New Blog Post (click on image below)
What is Public Health Genomics? A Day in the Invisible Life of Public Health Genomics.
Find EXACT phrase: lmp ovarian
Found 1 document.
A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarker
Find EXACT phrase: borderline ovarian
Found 2 documents, showing 1 - 2
- Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. | 2011 ASCO Annual Meeting Abstracts
... from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. | 2011 ASCO ...
... Background: Serous borderline ovarian tumors (SBOT) and low grade serous ovarian carcinomas (LG) ...
of HE4 and CA 125 in symptomatic patients with invasive epithelial
ovarian cancer. | 2011 ASCO Annual Meeting Abstracts
... were malignant. Borderline ovarian tumors were excluded from the analyses. A total of 115 cases ...
No documents found relating to your query/s.
Find EXACT phrase: gynecologic oncologist
Find EXACT phrase: gynaecologic oncologist
Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients| 2011 ASCO Abstract
Rectal and colon patients have similar rates of KRAS and PIK3CA mutations. However, BRAF mutations are more common in colon cancer. NRAS mutations are exclusively found in rectosigmoid cancers and may have a different biology than other colorectal cancers. These data suggest that primary tumor location may provide a means to enrich a population for a genotype-directed study.
Thursday, June 02, 2011
Find ALL words: palliative vs hospice
Found 35 documents, showing
Note: search term of 'clear cell' resulted in numerous renal clear cell abstracts
|No documents found relating to your query.|
Find EXACT phrase: clear cell ovarian